earnings
CM
NASDAQ · CMMB
Chemomab Therapeutics Ltd.
Healthcare · Biotechnology
$2.47
Up+$0.16 (+6.48%)
Updated Sep 16, 2026, 6:05 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.53M
- P/E ratio
- -1.45
- Dividend yield
- 0.00%
- 52-week range
- $1.35 – $3.58
- Volume
- 50.86K
- Avg. volume
- 157.57K
Price performance
CMMB price history
1M range · 20 trading sessions · Daily adjusted prices
CMMB closed at $2.47 after 20 trading sessions, up 29.32% for the selected period.
- Last close
- $2.47
- Period change
- +29.32%
- Period low
- $1.91
- Period high
- $2.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.46 | $2.5594 | $2.41 | $2.47 | 50.86K |
| Sep 14, 2026 | $2.575 | $2.5799 | $2.3767 | $2.45 | 105.63K |
| Sep 11, 2026 | $2.66 | $2.76 | $2.56 | $2.58 | 101.35K |
| Sep 10, 2026 | $2.665 | $2.6999 | $2.59 | $2.60 | 23.87K |
| Sep 9, 2026 | $2.75 | $2.80 | $2.59 | $2.69 | 76.86K |
| Sep 8, 2026 | $2.67 | $2.8792 | $2.66 | $2.75 | 95.94K |
| Sep 4, 2026 | $2.90 | $2.9408 | $2.71 | $2.71 | 118.51K |
| Sep 3, 2026 | $2.82 | $2.94 | $2.71 | $2.83 | 150.84K |
| Sep 2, 2026 | $2.73 | $2.84 | $2.71 | $2.73 | 47.82K |
| Sep 1, 2026 | $2.71 | $2.89 | $2.70 | $2.73 | 72.56K |
| Aug 31, 2026 | $2.70 | $2.80 | $2.64 | $2.72 | 42.19K |
| Aug 28, 2026 | $2.73 | $2.88 | $2.61 | $2.71 | 105.16K |
| Aug 27, 2026 | $2.57 | $2.9895 | $2.57 | $2.72 | 381.27K |
| Aug 26, 2026 | $2.36 | $2.65 | $2.32 | $2.59 | 421.37K |
| Aug 25, 2026 | $2.12 | $2.37 | $2.12 | $2.30 | 139.57K |
| Aug 24, 2026 | $2.16 | $2.27 | $2.08 | $2.17 | 80.19K |
| Aug 21, 2026 | $2.06 | $2.20 | $2.04 | $2.16 | 114.19K |
| Aug 20, 2026 | $2.06 | $2.10 | $1.95 | $2.07 | 83.36K |
| Aug 19, 2026 | $1.96 | $2.11 | $1.8801 | $2.09 | 118.77K |
| Aug 18, 2026 | $1.92 | $1.9201 | $1.87 | $1.91 | 17.21K |
Latest CMMB news
The latest Smart Investors Daily articles mentioning CMMB.
Stock researchResearch & News · SID Coverage
Loading stock research…

